Treatment of severe drooling with botulinum toxin in amyotrophic lateral sclerosis and Parkinson's disease: Efficacy and possible mechanisms

Acta Odontologica Scandinavica

Volumn 69, Issue 3, 2011, Pages 151-157

  Møller, Eigild ^a   Karlsborg, Merete ^a   Bardow, Allan ^b   Lykkeaa, Joan ^b   Nissen, Flemming H ^a   Bakke, Merete ^b  

^a BISPEBJERG HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Botulinum toxin type A; neurodegenerative disease; saliva; salivary gland; sialorrhoea

Indexed keywords

ACETYLCHOLINE; BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT; ONABOTULINUMTOXINA;

AGED; ALGORITHM; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CHEMISTRY; CLINICAL TRIAL; DRUG EFFECT; ENDOSCOPIC ECHOGRAPHY; FEMALE; HUMAN; HYPERSALIVATION; INJECTION; MALE; PARKINSON DISEASE; PAROTID GLAND; PROSPECTIVE STUDY; SALIVA; SALIVATION; SECRETION; SUBMANDIBULAR GLAND;

ACETYLCHOLINE; AGED; ALGORITHMS; AMYOTROPHIC LATERAL SCLEROSIS; BOTULINUM TOXINS, TYPE A; FEMALE; HUMANS; INJECTIONS; MALE; NEUROMUSCULAR AGENTS; PARKINSON DISEASE; PAROTID GLAND; PROSPECTIVE STUDIES; SALIVA; SALIVATION; SECRETORY RATE; SIALORRHEA; SUBMANDIBULAR GLAND; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 79955025790     PISSN: 00016357     EISSN: 15023850     Source Type: Journal    
DOI: 10.3109/00016357.2010.545035     Document Type: Article

References (41)

1. Meningaud JP, Pitak-Arnnop P, Chikhani L, Bertrand JC. Drooling of saliva: a review of the etiology and management options. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;101:48-57. (Pubitemid 41797038)
2. Hyson HC, Johnson A, Jog MS. Sublingual atropine for sialorrhoea secondary to parkinsonism: a pilot study. Mov Disord 2002;17:1318-20. (Pubitemid 36041348)
3. Kalf JG, Smit AM, Bloem BR, Zwarts MJ, Munneke M. Impact of drooling in Parkinson's disease. J Neurol 2007;254:1227-32. (Pubitemid 350112362)
4. Neppelberg E, Haugen DF, Thorsen L, Tysnes OB. Radiotherapy reduces sialorrhea in amyotrophic lateral sclerosis. Eur J Neurol 2007;14:1373-7. (Pubitemid 350135307)
5. Stone CA, O'Leary N. Systematic review of the effectiveness of botulinum toxin or radiotherapy for sialorrhoea in patients with amyotrophic lateral sclerosis. J Pain Symptom Manage 2009;37:246-58.
6. Tumilasci OR, Cersosimo MG, Belforte JE, Micheli FE, Benarroch EE, Pazo JH. Quantitative study of salivary secretion in Parkinson's disease. Mov Disord 2006;21:660-7. (Pubitemid 43792747)
7. Verma A, Steele J. Botulinum toxin improves sialorrhoea and quality of living in bulbar amyotrophic lateral sclerosis. Muscle Nerve 2006;34:235-7. (Pubitemid 44167807)
8. Heintze U, Birkhed D, Björn H. Secretion rate and buffer effect of resting and stimulated whole saliva as a function of age and sex. Swed Dent J 1983;7:227-8.
9. Meurman JH, Rantonen P. Salivary flow rate, buffering capacity, and yeast counts in 187 consecutive adult patients from Kuopio, Finland. Scand J Dent Res 1994;102:229-34.
10. Sreebny LM. Saliva in health and disease: an appraisal and update. Int Dent J 2000;50:140-61.
11. Sreebny LM, Valdini A. Xerostomia Part I. Relationship to other oral symptoms and salivary gland hypofunction. Oral Surg Oral Med Oral Pathol 1988:66;451-8.
12. Dawes C. The effect of flow rate and length of stimulation on the protein concentration in human parotid saliva. Arch Oral Biol 1967;12:783-8.
13. Dawes C. The effect of flow rate and duration of stimulation on the concentration of protein and the main electrolytes in human parotid saliva. Arch Oral Biol 1969;14:277-94.
14. Dawes C. The effects of flow rate and duration of stimulation on the concentrations of protein and the main electrolytes in human submandibular saliva. Arch Oral Biol 1974;19:887-95.
15. Molloy L. Treatment of sialorrhoea in patients with Parkinson's disease: best current evidence. Curr Opin Neurol 2007;20:493-8. (Pubitemid 47051999)
16. Lim M, Mace A, Nouraei SA, Sandhu G. Botulinum toxin in the management of sialorrhoea: a systematic review. Clin Otolaryngol 2006;31:267-72. (Pubitemid 44141089)
17. Tan EK. Botulinum toxin treatment of sialorrhea: comparing different therapeutic preparations. Eur J Neurol 2006;13(Suppl 1):60-4.
18. Teymoortash A, Sommer F, Mandic R, Schulz S, Bette M, Aumüller G, et al. Intraglandular application of botulinum toxin leads to structural and functional changes in rat acinar cells. Br J Clin Pharmacol 2007;152:161-7. (Pubitemid 47339910)
19. Bhidayasiri R, Truong DD. Expanding use of botulinum toxin. J Neurol Sci 2005;235:1-9. (Pubitemid 41039086)
20. Ellies M, Gottstein U, Rohrbach-Volland S, Arglebe C, Laskawi R. Reduction of salivary flow with botulinum toxin: extended report on 33 patients with drooling, salivary fistulas, and sialadenitis. Laryngoscope 2004:114;1856-60. (Pubitemid 39332268)
21. Giess R, Naumann M, Werner E, Riemann R, Beck M, Puls I, et al. Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2000;69:121-3. (Pubitemid 30410428)
22. Porta M, Gamba M, Bertacchi G, Vaj P. Treatment of sialorrhoea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders. J Neurol Neurosurg Psychiatry 2001;70:538-40. (Pubitemid 32269697)
23. Pal PK, Calne DB, Calne S, Tsui JK. Botulinum toxin A as treatment for drooling saliva in PD. Neurology 2000;54:244-7. (Pubitemid 30038773)
24. Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G. A randomized trial of botulinum toxin A for treatment of drooling. Neurology 2003;61:1279-81. (Pubitemid 37377556)
25. Mancini F, Zangaglia R, Cristina S, Sommaruga MG, Martignoni E, Nappi G, et al. Double-blind, placebocontrolled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 2003;8:685-8. (Pubitemid 36790285)
26. Dogu O, Apaydin D, Sevim S, Talas DU, Aral M. Ultrasound-guided versus 'blind' intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson's disease. Clin Neurol Neurosurg 2004;106:93-6. (Pubitemid 38299270)
27. Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebocontrolled study. Mov Disord 2006;21:704-7. (Pubitemid 43792756)
28. Nobrega AC, Roderigues B, Torres AC, Enzo A, Melo A. Does botulinum toxin decrease frequency and severity of sialorrhoea in Parkinson's disease? J Neurol Sci 2007;253:85-7. (Pubitemid 46185453)
29. Torres MAF, Aytes LB, Escoda CG. Salivary gland application of botulinum toxin for the treatment of sialorrhoea. Med Oral Patol Oral Cir Bucal 2007;12: E511-17.
30. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994;124(Suppl): 96-107.
31. Daniel SE, Lees AJ. Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm 1993;39(Suppl): 15-72.
32. Navazesh M, Christensen CM. A comparison of whole mouth resting and stimulated salivary measurement procedures. J Dent Res 1982;61:1158-62.
33. Jones JM, Watkins CA, Hand JS, Warren JJ, Cowen HJ. Comparison of three salivary flow rate assessment methods in an elderly population. Community Dent Oral Epidemiol 2000;28:177-84.
34. Bardow A, Nyvad B, Nauntofte B. Relations between medication intake, complaints of dry mouth, saliva flow rate, saliva composition, and the rate of human tooth demineralization in situ. Arch Oral Biol 2001;46:413-23. (Pubitemid 32289671)
35. Coté TR, Mohan AK, Polder JA, Walton MK, Braun MM. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol 2005;53:407-15. (Pubitemid 41195960)
36. Coffield JA, Yan X. Neuritogenic actions of botulinum neurotoxin A on cultured motor neurons. J Pharmacol Exp Ther 2009;330:352-8.
37. Meunier FA, Schiavo G, Molgo J. Botulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmission. J Physiol Paris 2002;96:105-13. (Pubitemid 34087038)
38. Schmidt-Nielsen B. The solubility of tooth substance in relation to the composition of saliva. Acta Odontol Scand 1946;7(Suppl 2):1-88.
39. Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache 2003;43(Suppl 1):16-24.
40. Poulsen JH. Secretion of electrolytes and water by salivary glands. In: Garrett JR, Ekström J, Anderson LC, editors. Glandular mechanisms of salivary secretion. Frontiers of oral biology, Vol. 10. Basel, Switzerland: Karger; 1998. p. 55-72.
41. Proctor GB. Secretory protein synthesis and constitutive (vesicular) secretion by salivary glands. In: Garrett JR, Ekström J, Anderson LC, editors. Glandular mechanisms of salivary secretion. Frontiers of oral biology, Vol. 10. Basel, Switzerland: Karger, 1998. p. 73-88.